National Lung Cancer Audit

Slides:



Advertisements
Similar presentations
National Prostate Cancer Audit Julie Nossiter, Project Manager Clinical Effectiveness Unit – Royal College of Surgeons.
Advertisements

NPCA data submission and reporting
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
National Prostate Cancer Audit Heather Payne, NPCA Oncological Clinical Lead Consultant Clinical Oncologist, UCL.
Chameleon Information Management Services Ltd NPCA Update from InfoFlex Sarah Waters Director of New Business.
The LCA: Implementing a Quality Assurance and Informatics Strategy to Enhance Cancer Care Dr Shelley Dolan LCA Clinical Director.
Resection rate for patients with tissue confirmation of NSCLC ( :England) First seen in centre with thoracic surgery? Number With a tissue diagnosis.
ILCOP web conference summary: Histological confirmation rates and diagnostics in lung cancer services 5 th July 2011.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
National Cancer Intelligence Network data usage 17 November 2015 – Veronique Poirier – Principal Cancer Analyst – NCIN.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
NMDT (%)Path (%)NOS (%)CNS (%) Weston Area Health  70.5  5.7  66.3  Yeovil District Hospital  54.9  22.9  82.9  University Hospitals.
Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.
Carlos Rocha Registry Manager National Cancer Registration Service (South West) West Dean Registration Improvement of Non-Melanoma skin cancer.
What data are available, and how are they accessed?
How clinicians use data to make an impact on clinical outcomes Andrew Brodbelt Consultant Neurosurgeon and Clinical Director of Neurosurgery, The Walton.
National Cancer Intelligence Network What data are available, and how are they accessed? Cancer Roadshow (London) 13 th April 2015 Vivian Mak, Information.
Cancer Outcomes and Services Dataset What is COSD? Implications for Providers and Networks.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
What data are collected? How, and who by? Karen Graham and Barry Plewa.
NCIN Roadshow: Cancer Data NCIN - Cancer Data Roadshow Public Health England | 2015 Elsita Payne Head of Registration – East Midlands and North West Branches.
Where can I find data on cancer? Victoria H Coupland London Knowledge and Intelligence Team 20 February 2014.
What does the cancer intelligence landscape look like now? Dr Mick Peake Clinical Lead, National Cancer Intelligence Network.
What data are available, and how are they accessed?
Uses of Cancer Data by RTPCT Cancer Chapter of the Public Health Annual Report 2003 Dr José M Ortega.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
How clinicians use data to make an impact on clinical outcomes Dr Mick Peake Clinical Lead, National Cancer Intelligence Network Consultant & Senior Lecturer.
What data are collected? How, and who by?. It’s complicated… ONS data.
Cheshire and Merseyside Strategic Clinical Networks Local Issues and Challenges 22 nd May 2015.
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
RCR Bladder Cancer Radiotherapy Audit 2016
The Quality Surveillance Team / Programme
Alfredo Addeo Lung NSSG 15th November 2016
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Brain imaging prior to lung cancer resection
How clinicians use data to make an impact on clinical outcomes
Challenges of Rare Cancers…
Oesophago–Gastric Cancer
Delivery of systemic therapy in Gloucestershire for NSCLC
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Curative treatment rates for patients diagnosed with
Segmented analysis of prostate cancer pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Oesophago–Gastric Cancer
WALES BOWEL CANCER AUDIT (WCBA) MDT DATA FOR PATIENTS DIAGNOSED AUGUST 2010-JULY 2011 PRINCE CHARLES HOSPITAL (PCH) MDT.
WALES BOWEL CANCER AUDIT (WCBA) MDT DATA FOR PATIENTS DIAGNOSED AUGUST 2010-JULY 2011 BRONGLAIS HOSPITAL (BRONGLAIS) MDT.
Review of NLCA cases detected through non –COSD routes 2016
Lung Cancer Audit to patient Reference Group
Patient Case 1 Patient Case 1: PET/CT Scan.
Prevention and Early Diagnosis of Cancer Ongar Health Centre Patient Forum 7th March 2018 Sue White Cancer Research UK Facilitator.
Pathway for patients with suspected Breast Cancer
Fundamental Concepts in the Diagnosis of Advanced NSCLC
Segmented analysis of the lung cancer median pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Product Development Catherine Donnelly
Results from the first National Lung Cancer Organisational Audit.
Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance
2018 National Mesothelioma Audit
Multi-Disciplinary Team Meeting Reforms
Published online September 20, 2017 by JAMA Surgery
Multi-Disciplinary Team Meeting Reforms
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Pathway for patients with suspected Breast Cancer
Quality Surveillance Programme
Breast Cancer SSG 14th November
Comparing the multiple sources of cancer treatment data
National Lung Cancer Audit
Calderdale and Huddersfield NHS Foundation Trust
York Teaching Hospitals NHS Trust
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Updates in Best Practices in Non-Small Cell Lung Cancer
Presentation transcript:

National Lung Cancer Audit Dr Ian Woolhouse University Hospital Birmingham Senior Clinical lead NLCA

Plan Data flows Online reporting portal Audit standards South West Network 2015 results Quality Improvement

Plan Data flows Online reporting portal Audit standards South West Network 2015 results Quality Improvement

English National Cancer Registration System New data flows Cancer Waiting Times Pathology full-text reports Radiotherapy Data (RTDS) Data from MDT software systems Chemotherapy Dataset (SACT) COSD Local imaging systems Molecular labs (EGFR) Patient Administration Systems ONS - Cancer and non- cancer deaths English National Cancer Registration System This is a diagram which represents the data feeds that will flow into ENCORE. Green boxes show feeds which will be sent directly to the Registry from each provider trust. These will be from Multi-Disciplinary Team (MDT) cancer tracking systems, full-text reports from Pathology systems, diagnostic and procedural information from Patient Administration Systems (PAS) and data from Radiology systems. The Orange represents national cancer datasets. These are the Radiotherapy Data Set (RTDS), the Systemic Anti-Cancer Therapy (SACT)/Chemotherapy dataset and National Cancer Waiting Times (CWT). Yellow boxes represent other feeds of data – Death information from the Office of National Statistics (ONS) and data from the Cancer Screening Programmes (Breast, Cervical and Bowel). “Cancer death” information will be provided for patients who have a mention of cancer on their death certificate, while “Non-Cancer Death” information is provided on all patients which has previously been flagged with ONS as having had cancer (but have died from another cause). The remaining white boxes show other data flows that will exist in ENCORE which either supplement existing data for COSD (HES, PET-CT and National Audits) or provide extra information that is not part of the COSD. Fully registered lung cancer case

Impact of new data flows Additional 6000 cases identified Older patients Less complete PS and stage Less likely to receive treatment Additional treatments identified Overall treatment rates similar

Plan Data flows Online reporting portal Audit standards South West Network 2015 results Quality Improvement

Online reporting portal https://nww.cancerstats.nhs.uk

Plan Data flows Online reporting portal Audit standards South West Network 2015 results Quality Improvement

Audit standards INDICATOR STANDARD Seen by CNS > 90% CNS present for diagnosis > 80% Histological confirmation > 75% NSCLC NOS rate < 15% Valid EGFR status recorded (non-squamous) PET before radical treatment > 95% Time from diagnosis to treatment SCLC < 2 weeks

Audit outcome indicators STANDARD % Stage I-II NSCLC receiving radical treatment Review outliers after risk adjustment % Stage IIIB-IV NSCLC PS 0-1 receiving chemotherapy % NSCLC EGFR M+ receiving TKI treatment % SCLC receiving chemotherapy Survival (median and 1 yr)

Plan Data flows Online reporting portal Audit standards South West Network 2015 results Quality Improvement

2015 results (preliminary)

2015 results (preliminary)

2015 results (preliminary)

Plan Data flows Online reporting portal Audit standards South West Network 2015 results Quality Improvement

Quality Improvement Two new QI leads Spotlight audits Regional workshops Targeted visits Sharing learning

What’s the end game?

nlca@rcplondon. ac. uk www. rcplondon. ac nlca@rcplondon.ac.uk www.rcplondon.ac.uk/resources/national-lung-cancer-audit